Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan, Binu Kandathilparambil Sasi, Elizabeth F. Cohen, Kiyomi Mashima, Hannah Cormier, Stacey M. Fernandes, Samantha J. Shupe, Roberta Santos Azevedo, Mariia Mikhaleva, Philippe Armand, David C. Fisher, Matthew S. Davids, Inhye E. Ahn, Michael Y. Tolstorukov, Mark A. Murakami, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2024-207527

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Salma Parvin, Binyamin Knisbacher, Aditi Aryal, Stacey M. Fernandes, Shlomi Medalion, Guy Leib, Johan Gustafsson, Shir Amit, Eden C Meidan, Nadav Y Klein, Savion Nafussy, Donna S. Neuberg, Catherine J. Wu, Jennifer R. Brown, Gad Getz, Anthony G. Letai

Blood (2024) 144 (Supplement 1): 76.

https://doi.org/10.1182/blood-2024-201594

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Blood (2024) 144 (Supplement 1): 587.

https://doi.org/10.1182/blood-2024-208951

Published: 2024

Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 583.

https://doi.org/10.1182/blood-2024-206576

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

Binu Kandathilparambil Sasi, Chiara Tarantelli, Elisa Civanelli, Eleonora Cannas, Stacey M Fernandes, Samantha J. Shupe, Michael Lahn, Lars van der Veen, Giusy Di Conza, Francesco Bertoni, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2023-180073

Published: 2023

Journal Articles

Defining the Drivers of Idelalisib-Related Early Autoimmune Toxicity in Chronic Lymphocytic Leukemia

Saurabh Yadav, Suraj Singh, Binu Kandathilparambil Sasi, Mandovi Chatterjee, Victor Barrera, Shannan Ho Sui, Stacey M Fernandes, Samantha J. Shupe, John-Hanson Machado, Mano Joseph Mathew, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6511.

https://doi.org/10.1182/blood-2023-186136

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Roberta Santos Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey M Fernandes, Samantha J. Shupe, Marissa Terra, Anisha Patel, Joseph Yu, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2023-180136

Published: 2023

Journal Articles

Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors

Aishath Naeem, Liang Li, Filippo Utro, Justin Cha, Junko Tsuji, Stacey M Fernandes, Roberta Santos Azevedo, Francesca Morelli, Zunqiu Wang, Samantha J. Shupe, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P Danysh, Alexandria Kluge, Matthew S Davids, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2023-186052

Published: 2023

Journal Articles

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Kiyomi Mashima, Mariia Mikhaleva, Stacey M Fernandes, Samantha J. Shupe, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6507.

https://doi.org/10.1182/blood-2023-187406

Published: 2023

Journal Articles

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Mariia Mikhaleva, Svitlana Tyekucheva, Kiyomi Mashima, Stacey M Fernandes, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2023-173738

Published: 2023

Journal Articles

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Blood (2023) 142 (5): 421–433.

https://doi.org/10.1182/blood.2022016600

Published: 2023

Includes: Supplemental data

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Anisha V. Patel, Abirami Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 7038–7040.

https://doi.org/10.1182/blood-2022-162707

Published: 2022

Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Blood (2022) 140 (Supplement 1): 1530–1533.

https://doi.org/10.1182/blood-2022-160335

Published: 2022

Journal Articles

Integrating High-Throughput Dynamic BH3 Profiling and Molecular Phenotyping to Identify Therapeutic Vulnerabilities in CLL

Salma Parvin, Binyamin A. Knisbacher, Aditi Aryal, Stacey M. Fernandes, Donna S. Neuberg, Catherine J. Wu, Jennifer R. Brown, Gad Getz, Anthony G. Letai

Blood (2022) 140 (Supplement 1): 6983–6984.

https://doi.org/10.1182/blood-2022-169352

Published: 2022

Journal Articles

Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Blood (2022) 140 (Supplement 1): 6981–6982.

https://doi.org/10.1182/blood-2022-160279

Published: 2022

NARROW

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

Defining the Drivers of Idelalisib-Related Early Autoimmune Toxicity in Chronic Lymphocytic Leukemia

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Integrating High-Throughput Dynamic BH3 Profiling and Molecular Phenotyping to Identify Therapeutic Vulnerabilities in CLL

Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only